GCN2iB acetate 是一种 ATP 竞争性的选择性 GCN2 抑制剂(IC50 为 2.4 nM),可抑制 GCN2 通路的激活并上调 GPX4,增强 ASNase 对急性淋巴细胞白血病的抗癌作用,同时提升左心室射血分数、降低空腹血糖并减少心肌纤维化,因此可用于急性淋巴细胞白血病、急性髓系白血病和糖尿病心肌病的相关研究。
产品编号: MS-T70440 CAS No.: 2183470-13-3 分子式: C20H16ClF2N5O5S 分子量: 511.89
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

GCN2iB acetate 是一种 ATP 竞争性的选择性 GCN2 抑制剂(IC50 为 2.4 nM),可抑制 GCN2 通路的激活并上调 GPX4,增强 ASNase 对急性淋巴细胞白血病的抗癌作用,同时提升左心室射血分数、降低空腹血糖并减少心肌纤维化,因此可用于急性淋巴细胞白血病、急性髓系白血病和糖尿病心肌病的相关研究。

生物实验数据

生物活性 GCN2iB acetate is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM that inhibits activation of the GCN2 pathway and upregulates GPX4, enhances the anticancer effect of ASNase against acute lymphoblastic leukemia, and increases left ventricular ejection fraction while lowering fasting blood glucose and reducing myocardial fibrosis, making it useful for research on acute lymphoblastic leukemia, acute myeloid leukemia, and diabetic cardiomyopathy.
IC50 & Target

GPX4

 

GCN2

2.4 nM (IC50)

体外研究
(In Vitro)

GCN2iB (1 μmol/L) acetate 可强效抑制重组 GCN2,其 IC50 为 2.4 nmol/L,且具有高激酶选择性,在包含 468 种激酶的筛选组中仅表现出极低的脱靶抑制活性。
GCN2iB (10-9-10-5 M; 72 h) acetate 可增强 ASNase 在 GCN2-WT MEF 细胞中的抗增殖作用,但在 GCN2-KO MEF 细胞中无此作用,这证实了其靶向 GCN2 的抑制活性。
GCN2iB (1 μmol/L; 72 h) acetate 可使 CCRF-CEM、MV-4-11 和 SU.86.86 细胞对 ASNase 诱导的抗增殖作用增敏。

Cell Proliferation Assay

Cell Line: GCN2-WT MEF cells
Concentration: 10-9-10-5 M
Incubation Time: 72 h
Result: Exhibited no antiproliferative effect when combined with ASNase in GCN2-KO MEF cells.
Robustly reduced viability of cells when combined with ASNase in GCN2-WT MEF cells.
体内研究
(In Vivo)

GCN2iB (10 mg/kg;每日 2 次;连续 7 天) acetate 与 1,000 U/kg ASNase 协同作用,可强效抑制小鼠体内 CCRF-CEM 急性淋巴细胞白血病 (ALL) 异种移植瘤的生长,且具有统计学意义的交互作用 (P = 0.0007)。
GCN2iB (10 mg/kg;每日 2 次;每周 3 天;持续 28 天) acetate 与 1,000 U/kg ASNase 协同作用,可改善播散性 MOLT-3 急性淋巴细胞白血病 (ALL) 小鼠的存活率。
GCN2iB (3 mg/kg;腹腔注射;隔日一次;持续 6 周) acetate 可改善高脂饮食联合 Streptozotocin (MS-Q80520) 诱导的糖尿病小鼠的心脏收缩功能,使左心室射血分数提升 34.7%,同时降低空腹血糖、减少心肌脂质蓄积、氧化应激及纤维化。
GCN2iB (3 mg/kg;腹腔注射;每 2 天 1 次;持续 6 周) acetate 可改善 db/db 小鼠的心脏收缩功能,使左心室射血分数提升 14.5%,同时降低空腹血糖、减少心肌脂质蓄积并缓解氧化应激。

Animal Model: SCID
Dosage: 10 mg/kg; co-administered with 1,000 U/kg ASNase
Administration: twice daily; daily; 7 days
Result: Did not significantly affect tumor growth (P = 0.99).
Elicited potent antitumor activity (P = 0.0002) with synergistic effects (main effect of ASNase, P = 0.0053; main effect of GCN2iB, P = 0.0006; interaction effect, P = 0.0007) when combined with ASNase.
Achieved a tumor growth inhibition resulting in a treatment over control (T/C) value significantly lower than vehicle, ASNase alone, or GCN2iB alone when combined with ASNase.
Animal Model: C57BL/6J (male; diabetic cardiomyopathy induced by 8 weeks of high-fat diet + intraperitoneal streptozotocin injection, fasting blood glucose ≥ 11.1 mmol/L)
Dosage: 3 mg/kg
Administration: i.p.; every other day; 6 weeks
Result: Decreased fasting blood glucose to 11.18 mmol/L.
Decreased body weight to 28.94 g.
Increased left ventricular ejection fraction to 70.41%.
Increased heart weight to body weight ratio.
Decreased myocardial fibrosis, myocyte cross-sectional area, and cardiac triglyceride levels.
Decreased mRNA levels of hypertrophic/fibrotic genes (ANP, BNP, β-MHC, Calm3, Collagen-I, Collagen-III) and lipid metabolism-related genes (CD36, Fasn, Plin4, Plin2, Pparγ, SCD1, Srebp1c).
Decreased myocardial 3'-NT, 4-HNE, and superoxide levels.
Upregulated antioxidative genes (Gpx1/4/7, Gstp1/2, Mt1, Prdx2, Trx2) and proteins (GPX4, PRDX2, TRX2).
Decreased protein expression of ANP, FAS, and CIDEA.
Increased myocardial phosphocreatine and taurine levels.
Upregulated oxidative phosphorylation, glycolysis/gluconeogenesis, proteasome, and amino acid biosynthesis pathway genes.
Downregulated hypertrophic cardiomyopathy, dilated cardiomyopathy, and PPAR signaling pathway genes associated with disease progression.
Animal Model: leptin receptor deficient (db/db) (male; spontaneous type 2 diabetes due to leptin receptor deletion)
Dosage: 3 mg/kg
Administration: i.p.; every other day; 6 weeks
Result: Decreased fasting blood glucose to 9.64 mmol/L.
Decreased body weight to 44.67 g.
Decreased heart weight to 145.7 mg.
Increased left ventricular ejection fraction to 84.05%.
Decreased cardiac triglyceride, 3'-NT, and 4-HNE levels.
Decreased mRNA levels of hypertrophic/fibrotic genes (β-MHC, BNP, Calm3, Collagen-I, Collagen-III) and lipid metabolism-related genes (Fasn, Srebp1c).
Increased mRNA levels of oxidative phosphorylation genes (Atcg1, Atp5d, Atp5j1, Ndufa8, Ndufs6).
Decreased protein expression of ANP, FAS, CD36, and Cidea.
Increased protein expression of GPX4, PRDX2, and TRX2.

化学信息

分子量 511.89
分子式 C20H16ClF2N5O5S
CAS No. 2183470-13-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础